MA21800A1 - Procede de preparation de produits nouveaux. - Google Patents

Procede de preparation de produits nouveaux.

Info

Publication number
MA21800A1
MA21800A1 MA22044A MA22044A MA21800A1 MA 21800 A1 MA21800 A1 MA 21800A1 MA 22044 A MA22044 A MA 22044A MA 22044 A MA22044 A MA 22044A MA 21800 A1 MA21800 A1 MA 21800A1
Authority
MA
Morocco
Prior art keywords
formula
disorders
group
preparation process
new product
Prior art date
Application number
MA22044A
Other languages
English (en)
Inventor
Demandeurs
Original Assignee
Beecham Group Plc
Beecham Wuelfing Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc, Beecham Wuelfing Gmbh & Co Kg filed Critical Beecham Group Plc
Publication of MA21800A1 publication Critical patent/MA21800A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA22044A 1989-03-23 1990-03-20 Procede de preparation de produits nouveaux. MA21800A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898906792A GB8906792D0 (en) 1989-03-23 1989-03-23 Treatment and compounds

Publications (1)

Publication Number Publication Date
MA21800A1 true MA21800A1 (fr) 1990-12-31

Family

ID=10653940

Family Applications (1)

Application Number Title Priority Date Filing Date
MA22044A MA21800A1 (fr) 1989-03-23 1990-03-20 Procede de preparation de produits nouveaux.

Country Status (27)

Country Link
US (4) US5734051A (fr)
EP (2) EP1120417A3 (fr)
JP (1) JP2510889B2 (fr)
KR (1) KR0160768B1 (fr)
CN (1) CN1031641C (fr)
AT (1) ATE213498T1 (fr)
AU (1) AU629315B2 (fr)
CA (1) CA2012686C (fr)
CZ (1) CZ391891A3 (fr)
DE (1) DE69033915T2 (fr)
DK (1) DK0389282T3 (fr)
ES (1) ES2173074T3 (fr)
FI (1) FI95033C (fr)
GB (1) GB8906792D0 (fr)
HK (1) HK1040392A1 (fr)
HU (1) HU207081B (fr)
IL (1) IL93832A (fr)
MA (1) MA21800A1 (fr)
MY (1) MY109737A (fr)
NO (1) NO175592C (fr)
NZ (1) NZ233021A (fr)
PL (1) PL164811B1 (fr)
PT (1) PT93527B (fr)
SA (1) SA90100215B1 (fr)
SK (1) SK391891A3 (fr)
ZA (1) ZA902170B (fr)
ZW (1) ZW3690A1 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021422A (en) * 1989-06-08 1991-06-04 Senetek Plc Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
ES2148170T3 (es) * 1990-12-21 2000-10-16 Beecham Group Plc Derivados de xantina.
ATE141791T1 (de) 1991-07-05 1996-09-15 Byk Gulden Lomberg Chem Fab Verwendung substituierter pyridazine gegen dermatosen
AU3725893A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
CA2093403C (fr) * 1992-04-08 1999-08-10 Fumio Suzuki Agent de traitement de la maladie de parkinson
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
GB9215633D0 (en) * 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US6066641A (en) * 1994-12-13 2000-05-23 Euro-Celtique S.A. Aryl thioxanthines
DE69531555T2 (de) 1994-12-13 2004-06-17 Euroceltique S.A. Dreifachsubstituierte thioxanthine
JPH11505241A (ja) * 1995-05-19 1999-05-18 カイロサイエンス・リミテッド キサンチン類およびこれらの治療的使用
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
ATE325610T1 (de) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
AR015190A1 (es) * 1997-10-23 2001-04-18 Smithkline Beecham Corp Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CA2715683A1 (fr) 1999-08-21 2001-03-01 Nycomed Gmbh Combinaison synergiste
EP1265861A2 (fr) 2000-03-16 2002-12-18 Inflazyme Pharmaceuticals, Ltd. Inhibiteurs benzyles de pde4
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
EP1953162B9 (fr) * 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Dérivé de xanthine, sa fabrication et son utilisation en tant que médicament
CA2446828C (fr) * 2001-05-08 2011-01-04 Blanchette Rockefeller Neurosciences Institute Antagonistes du recepteur de l'adenosine a1 permettant de traiter des troubles de la memoire et de l'apprentissage induits par une hypoxie
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
WO2003015789A2 (fr) * 2001-08-15 2003-02-27 Leo Pharma A/S Composition pharmaceutique pour application cutanee
EP1421084B1 (fr) 2001-08-28 2008-05-14 Schering Corporation Inhibiteurs polycycliques de la phosphodiesterase v de la guanine
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
DE602004006756T2 (de) * 2003-07-31 2008-01-24 Schering Corp. Metabolite eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
EP1709966A4 (fr) * 2003-12-09 2009-04-29 Agent preventif et/ou therapeutique pour un dysfonctionnement cerebral severe
AU2005212816C1 (en) * 2004-02-14 2010-03-04 Glaxosmithkline Llc Novel compounds
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PT1912991E (pt) 2005-08-10 2011-01-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de hm74a
JP2009533330A (ja) * 2006-03-21 2009-09-17 ドクター レディズ ラボラトリーズ リミテッド ドセタキセルの多形体およびプロセス
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
EP3366304B1 (fr) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Traitement du diabète
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
WO2013010964A1 (fr) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Quinazolines substituées, la préparation de celles-ci et l'utilisation de celles-ci dans des compositions pharmaceutiques
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
SI3251675T1 (sl) 2015-01-30 2021-08-31 Shanton Pharma Pte. Ltd. Preprečevanje ali zdravljenje sečnokislinske ali protinske bolezni
PT3280417T (pt) 2015-04-08 2020-10-30 Lewis And Clark Pharmaceuticals Inc Carbamatos de alquinilo substituídos com xantina/carbamatos reversos utilizados como antagonistas de adenosina a2b
EP3165224A1 (fr) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Utilisation d'inhibiteurs de pde4 pour la prophylaxie et/ou la thérapie de la dyslipoproteinémie et des troubles apparentés
WO2017089347A1 (fr) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
EP3468562A1 (fr) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinaisons de linagliptine et de metformine
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US757328A (en) * 1903-02-07 1904-04-12 Boehringer & Soehne Art of preparing xanthin derivatives.
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
US2534813A (en) * 1950-01-21 1950-12-19 Searle & Co 8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
CH654008A5 (fr) * 1979-05-22 1986-01-31 Nestle Sa Procede de preparation de 1,3,7-trialkylxanthines.
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4666914A (en) * 1985-05-13 1987-05-19 Schering Corporation Anti-inflammatory and anti-allergic substituted-2,3-dihydro-6-(hydroxy)pyrimido[2,1-f]-purine-4,8(1H,9H)-diones
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
AU603850B2 (en) 1986-12-22 1990-11-29 Dr. Lo Zambeletti S.P.A. Novel piperidine derivatives
IT1197516B (it) * 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono

Also Published As

Publication number Publication date
NO901300L (no) 1990-09-24
JP2510889B2 (ja) 1996-06-26
DE69033915T2 (de) 2002-10-10
EP1120417A3 (fr) 2001-08-08
EP0389282B1 (fr) 2002-02-20
EP0389282A3 (fr) 1992-07-01
CN1047502A (zh) 1990-12-05
ZA902170B (en) 1991-03-27
IL93832A (en) 1994-07-31
EP1120417A2 (fr) 2001-08-01
KR900013962A (ko) 1990-10-22
DK0389282T3 (da) 2002-06-03
PL164811B1 (pl) 1994-10-31
DE69033915D1 (de) 2002-03-28
HK1040392A1 (zh) 2002-06-07
US5981535A (en) 1999-11-09
US5734051A (en) 1998-03-31
ES2173074T3 (es) 2002-10-16
HU901792D0 (en) 1990-06-28
IL93832A0 (en) 1990-12-23
GB8906792D0 (en) 1989-05-10
HU207081B (en) 1993-03-01
PT93527B (pt) 1996-08-30
FI95033C (fi) 1995-12-11
CN1031641C (zh) 1996-04-24
HUT54155A (en) 1991-01-28
SK391891A3 (en) 2000-12-11
JPH02273676A (ja) 1990-11-08
NO175592C (no) 1994-11-02
CA2012686A1 (fr) 1990-09-23
MY109737A (en) 1997-05-31
CZ391891A3 (en) 1993-11-17
KR0160768B1 (ko) 1998-12-01
NZ233021A (en) 1993-12-23
FI901447A0 (fi) 1990-03-22
AU629315B2 (en) 1992-10-01
US6531600B1 (en) 2003-03-11
FI95033B (fi) 1995-08-31
NO901300D0 (no) 1990-03-21
US6180791B1 (en) 2001-01-30
EP0389282A2 (fr) 1990-09-26
PT93527A (pt) 1990-11-07
ZW3690A1 (en) 1991-02-06
CA2012686C (fr) 1999-12-07
AU5208390A (en) 1990-09-27
SA90100215B1 (ar) 2001-10-07
ATE213498T1 (de) 2002-03-15
NO175592B (no) 1994-07-25

Similar Documents

Publication Publication Date Title
MA21800A1 (fr) Procede de preparation de produits nouveaux.
DE10199003I2 (fr)
BR8704582A (pt) Processo para preparar derivados de piridinacarboxamida
GB8919417D0 (en) Novel compounds
FI101226B1 (fi) Menetelmä lääkeaineena käyttökelpoisten 2-[2-(karbonyyli)pyrrolidin-4-yylitio]-6-(1-hydroksietyyli)-1-metyylikarbapen-2-eemi-3-karboksyylihappojohdannaisten valmistamiseksi
FR2592879B1 (fr) Nouveaux derives de la decahydroquinoleine, leur procede de preparation, les intermediaires de preparation, leur application a titre de medicaments et les compositions les renfermant
ES2064461T3 (es) Derivados de xantina, procedimiento para su preparacion y composicion farmaceutica.
ES482787A1 (es) Un procedimiento para preparar derivados de flavano, mono- di-y tri-sustituidos.
OA09119A (fr) Nouveaux céphèmes et leur préparation.
PT87277A (pt) Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same
FI104071B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents£b|atsepiinijohdannaisten valmistamiseksi
NO173276C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive 1,4-disubstituerte-piperidinylderivater
ATE110376T1 (de) Biphenyl-derivate, verfahren zu deren herstellung und deren zwischenprodukte.
WO2001035938A3 (fr) Derives tetrahydrothiopyran-4-ol pharmacologiquement actifs, leur procede de fabrication et leur utilisation
FI101071B (fi) Menetelmä terapeuttisesti käyttökelpoisten 3,4-dihydroisokinoliini-N-o ksidien valmistamiseksi
ES8203828A1 (es) Procedimiento para la obtencion de bis (fenoxiacetatos sus- tituidos)de n-alcohil-dialcanolaminas